Lechleiter inherits the biggest problem facing Big Pharma today: beefing up the pipeline in the face of disappearing blockbusters. And having been an industry insider for nearly 30 years, he understands as well as anyone it's like playing the lottery, with a fat pay-off but long odds.
{"contentId":"1396521","authorDomain":"dojc"}
{"contentId":"1396521","authorDomain":"dojc"}
- Enjoy this article? Help vote it up the 'Vine.
- Public Discussion (0)
{"canLink":false,"threadId":0,"isPrivate":false}
You're in Easy Mode. If you prefer, you can use XHTML Mode instead. |
As a new user, you may notice a few temporary content restrictions. Click here for more info.



